WSW, NY, October 21st, 2026, FinanceWireRecent acquisitions and licensing deals reveal what drugmakers want next: different ...
Rhythm Pharmaceuticals is transitioning from a development stage to a commercial rare disease leader, leveraging its IMCIVREE franchise for biologically defined obesity. IMCIVREE’s recent FDA and EU ...
Recent developments in the Prader-Willi syndrome treatment market, including progress on targeted therapies such as Rhythm ...
Launch follows MHLW approval of IMCIVREE for acquired hypothalamic obesity and inclusion on Japan's National Health Insurance ...
US-based biotechnology company Superluminal Medicines has completed a $60m Series B financing round to support its research into therapies for rare genetic forms of obesity and hypothalamic obesity.
Rhythm Pharmaceuticals, Inc. remains a compelling rare-disease obesity platform, with a maintained Buy rating driven by progress in HO, PWS, and oral MC4R agonists. PWS Phase 2 data for IMCIVREE show ...
Although the number of U.S. children under age 12 with obesity who are prescribed the weight-loss drugs Saxenda, Wegovy and Zepbound remains low, it was 310 times higher in June 2026 than in 2019, ...
Add Yahoo as a preferred source to see more of our stories on Google. Seattle Children's Hospital Seattle Children's said a clinical trial published this week in The New England Journal of Medicine ...
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) on Wednesday released topline results from its Phase 2 trial evaluating bivamelagon (formerly LB54640), an investigational oral melanocortin-4 receptor (MC4R ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results